AMG 133, Placebo for Maridebart Cafraglutide
20210181
Phase 3 small_molecule active
Quick answer
AMG 133, Placebo for Maridebart Cafraglutide for Chronic Weight Management is a Phase 3 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Chronic Weight Management
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active